
Beta-Caryophyllene Bioavailability: Why the Delivery Formula Changes Absorption
Updated: 5 days ago

Two supplements can contain exactly the same amount of beta-caryophyllene yet deliver very different amounts of the compound into the bloodstream.
How is that possible?
The answer lies partly in what happens between swallowing a supplement and absorbing its active ingredients.
Beta-caryophyllene (BCP) is a naturally occurring terpene found in cloves, black pepper and other botanicals. It is attracting scientific attention because of its interaction with cannabinoid type 2 (CB2) receptors and other biological signaling pathways.
But BCP has an important formulation challenge: it mixes readily with oils and poorly with water.
That property makes its delivery system especially relevant.
Human research has demonstrated that a self-emulsifying BCP formulation produced greater systemic exposure and faster absorption than ordinary BCP oil under controlled study conditions. Additional research has investigated nanoemulsifying systems in animals.
The most useful question is what these findings reveal about absorption—and how to evaluate different BCP products without assuming that every advanced formulation performs identically.
Why is beta-caryophyllene difficult to formulate for oral absorption?
Beta-caryophyllene is a lipophilic compound.
Lipophilic means that a molecule has an affinity for lipid environments such as oils and fats.
The digestive tract, however, contains considerable water.
For an orally administered compound to be absorbed, it must become available in a form that can interact with the digestive environment and pass through biological barriers.
For lipophilic compounds, this can involve several processes, including dispersion, digestion, transport through intestinal fluids and partitioning into cell membranes.
A substance that does not disperse well in water may present formulation challenges even when the ingredient itself is biologically active.
This is why formulation scientists investigate carrier systems that help lipophilic ingredients disperse, remain stable and become available for absorption.
With BCP, those investigations have produced measurable human pharmacokinetic findings.
What does bioavailability actually measure?
Bioavailability describes the rate and extent to which an administered compound reaches systemic circulation.
Researchers often study bioavailability by measuring the concentration of a compound in blood samples collected at different times after administration.
Three measurements are especially useful.
AUC: total measured exposure over time
AUC stands for area under the concentration-time curve.
It summarizes how much systemic exposure occurs across a defined observation period.
When two formulations deliver the same amount of BCP, a higher measured AUC generally indicates greater systemic exposure during the measurement window.
Cmax: the highest measured concentration
Cmax is the maximum concentration observed in blood or plasma after administration.
A higher Cmax means that the concentration reached a higher measured peak.
A higher peak does not automatically mean that the product produces a better clinical outcome.
Tmax: time to the highest measured concentration
Tmax is the time at which the maximum measured concentration occurs.
A shorter Tmax indicates that the peak was reached sooner.
These measurements answer questions about absorption and exposure.
They do not, by themselves, establish whether a supplement reduces inflammation, improves a symptom or produces a particular health benefit.
What did the 2022 human BCP absorption study discover?
In 2022, Mödinger and colleagues published an important study in Molecules comparing two oral preparations of beta-caryophyllene.
The researchers enrolled 24 healthy adults, including 12 men and 12 women.
The study used a randomized, double-blind, crossover design.
Each participant received a single 100 mg dose of BCP in two different preparations, separated by a washout period.
One preparation used ordinary BCP oil.
The other used VESIsorb, a proprietary self-emulsifying drug delivery system, often abbreviated SEDDS.
Blood samples were collected over 24 hours to measure BCP concentrations.
The results were striking
The researchers found that the tested self-emulsifying formulation produced:
- Approximately 2.2 times the AUC over 12 hours. - Approximately 2.0 times the AUC over 24 hours. - Approximately 3.6 times the peak plasma concentration. - A shorter mean time to maximum concentration: approximately 1.43 hours versus 3.07 hours.
These measurements demonstrated a substantial difference in systemic exposure between the two tested preparations.
Original human study: Mödinger et al., 2022 — Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using VESIsorb Formulation Technology.
How different were the measured blood concentrations?
The study provides a useful numerical comparison.
Pharmacokinetic measurement | Self-emulsifying BCP | Ordinary BCP oil |
|---|---|---|
Administered BCP | 100 mg | 100 mg |
Mean Cmax | 204.6 ng/mL | 58.22 ng/mL |
Mean AUC, 0–12 hours | 549.5 ng·h/mL | 260.7 ng·h/mL |
Mean AUC, 0–24 hours | 553.4 ng·h/mL | 305.9 ng·h/mL |
Mean Tmax, approximately | 1.43 hours | 3.07 hours |
The comparison makes the central finding easier to understand.
The researchers administered the same quantity of BCP, but the measured exposure differed considerably.
The self-emulsifying system also produced an earlier peak.
This illustrates why the amount printed on a supplement label and the amount reaching circulation are different measurements.
However, the study compared two specific preparations under fasting conditions.
Its numerical findings cannot automatically be assigned to other emulsified, liposomal or powdered BCP products.
How do self-emulsifying delivery systems work?
Self-emulsifying delivery systems combine ingredients that help an oil-based preparation disperse when it encounters gastrointestinal fluids.
These systems commonly contain a lipid phase and surfactants selected to support the formation of dispersed droplets.
Under suitable conditions, the preparation can form fine droplets as it mixes with fluid.
The resulting dispersion may improve the availability of lipophilic molecules for subsequent absorption processes.
The characteristics of the resulting droplets depend on the composition and manufacturing process.
Important variables include droplet size, stability, the type of lipid, surfactant characteristics and the behavior of the formulation under digestive conditions.
The 2022 human study demonstrated that the particular VESIsorb-based BCP preparation produced greater systemic exposure than the comparison oil.
It did not establish that all self-emulsifying systems produce the same improvement.
What did the 2026 nanoemulsion study add?
Another important investigation appeared in the Journal of Pharmacy and Pharmacology, Volume 78, Issue 2, in February 2026.
Chagas-Almeida and colleagues investigated a self-nanoemulsifying delivery system containing beta-caryophyllene derived from clove oil.
The researchers prepared a formulation containing BCP, a surfactant and a lipophilic phase.
They examined its physical characteristics, including droplet behavior and stability in different fluid environments.
The study then investigated oral bioavailability and inflammation-related experimental outcomes in rats.
This provided an additional research model for examining how a lipid-based delivery system can influence BCP exposure.
Original research: Improving the Oral Bioavailability and Anti-Inflammatory Potential of Clove Oil-Derived β-Caryophyllene with a Self-Nanoemulsifying Drug Delivery System.
DOI: 10.1093/jpp/rgaf105
What was corrected in May 2026?
The journal published a formal correction in May 2026.
The correction addressed two publication details: a graphical abstract omitted from the original version and the spelling of the first author's name, now given as Any Carolina Chagas-Almeida.
The correction notice does not identify a change to the experimental results.
Official correction: Journal of Pharmacy and Pharmacology — Correction, DOI 10.1093/jpp/rgag053.
The original paper and its correction should be linked together when the study is cited.
Why does the animal model matter?
The 2026 investigation studied rats, whereas the 2022 absorption study involved human volunteers.
Both contribute to formulation research, but they answer questions at different evidence levels.
The animal work helps scientists examine delivery-system behavior and biological responses under controlled experimental conditions.
The human study directly measured systemic BCP exposure in people.
Neither study demonstrates the clinical effectiveness of every commercial nanoemulsion or liposomal formulation.
Are liposomal and self-emulsifying formulations the same?
They are related through the broader field of lipid-based delivery, but their structures and manufacturing approaches differ.
A liposome is a vesicle built from one or more phospholipid bilayers.
Its structure can accommodate different kinds of ingredients depending on the composition and formulation design.
A self-emulsifying system is designed to form a dispersed emulsion when exposed to appropriate fluids.
A nanoemulsion describes a dispersed system with small droplets whose properties depend on formulation and processing conditions.
A powdered delivery system can use carriers, emulsifiers or other technologies to make an oil-compatible ingredient easier to measure, disperse or incorporate into a product.
The terminology describes different formulation approaches.
It does not create a universal ranking in which every liposome, nanoemulsion or powder absorbs more effectively than every oil.
What matters is the tested finished formulation.
For an explanation of liposomal structures, read Liposomal Beta-Caryophyllene: How the Delivery Format Works.
What makes particle size important?
Formulation research often measures the size and distribution of particles or droplets.
These characteristics can influence how a system disperses, interacts with its environment and remains stable.
Small droplets may increase the available surface area between a lipid phase and surrounding fluid.
But particle size is only one factor.
A small particle can still release an ingredient poorly, become unstable, aggregate, or behave differently after digestion.
A formulation's performance depends on several interacting characteristics.
For this reason, a product described as nano should not be assumed to have a particular human bioavailability improvement without supporting measurements.
Does greater absorption mean greater effectiveness?
This is the question that matters most when translating delivery research into clinical claims.
Absorption measures what happens to a compound after administration.
Clinical effectiveness measures whether a particular intervention changes a meaningful outcome in people.
Those are separate questions.
A formulation that produces higher plasma concentrations could produce different biological exposure.
But the significance of that exposure depends on the compound, the relevant target, the administered amount, safety and the outcome being studied.
Researchers may need additional evidence involving dose-response relationships, tissue exposure, receptor engagement and clinical measurements.
Greater systemic exposure is a pharmacokinetic finding, not automatic proof of greater clinical benefit.
This distinction is especially important in beta-caryophyllene research because much of the biological literature involves cells or animals rather than controlled human trials of finished supplements.
How should BCP formulation studies be compared?
Before drawing conclusions from an absorption study, examine what was actually tested.
Question | Why it matters |
|---|---|
Was the study conducted in humans? | Human absorption data are more directly applicable to human exposure |
Was BCP administered alone or in a blend? | Companion ingredients may influence the result |
What was the comparison preparation? | A ratio such as “2× greater” applies to that comparison |
Was the same BCP dose administered? | Dose differences can change measured concentrations |
Which measurement was reported? | AUC, Cmax and Tmax describe different aspects of exposure |
Was the finished commercial product tested? | Results from another carrier system may not transfer |
Were clinical outcomes measured? | Blood concentrations do not establish health benefits |
This framework makes published research useful when comparing products.
It also helps prevent a common misunderstanding: borrowing an absorption result from one proprietary delivery system and applying it to a different product simply because the products use similar terminology.
How does this research relate to BCPlus formulations?
Blair Medical Group develops physician-formulated BCPlus supplements using different approaches for delivering beta-caryophyllene.
Two oral products illustrate distinct formulation strategies.
BCPlus Oral Liposomal Drops
BCPlus Oral Liposomal Drops are a liquid preparation containing clove-derived BCP.
The formulation uses phospholipid-based delivery components, including sunflower lecithin, to support a water-dispersible oral format.
The product provides a liquid option for readers who prefer measured oral administration.
The 2022 VESIsorb study examined a different proprietary formulation.
Its absorption ratios cannot be presented as measured results for BCPlus Oral Liposomal Drops without product-specific comparative testing.
BCPlus Nano Powder
BCPlus Nano Powder combines plant-derived BCP with formulation ingredients including medium-chain triglycerides, inulin and an emulsifier.
The powder format is intended to make the compound convenient to measure and incorporate into oral use.
Its design reflects the broader challenge of formulating a lipophilic compound.
However, the human absorption performance of the finished BCPlus Nano Powder has not been established by the VESIsorb study or by the 2026 rat study.
What should the next BCP bioavailability studies investigate?
The next important step is to compare finished BCP formulations under standardized human study conditions.
A carefully designed investigation could administer equal amounts of BCP and measure plasma concentrations over time.
Researchers could compare AUC, Cmax and Tmax while accounting for meal timing, individual variation and formulation stability.
Additional studies could examine repeated dosing rather than a single administration.
For clinical applications, exposure measurements would need to be connected to appropriate biological or health outcomes.
That would help clarify which formulation characteristics influence absorption and whether those differences have practical relevance.
Frequently Asked Questions
Why is beta-caryophyllene difficult to absorb?
BCP is lipophilic and has poor water miscibility. Its behavior in gastrointestinal fluids can influence how readily it becomes available for absorption. Formulation systems can alter dispersion and systemic exposure.
Has improved BCP bioavailability been demonstrated in humans?
Yes. A 2022 randomized crossover study in 24 healthy adults measured higher blood exposure and faster absorption with a specific VESIsorb self-emulsifying formulation compared with ordinary BCP oil.
What does a 3.6-fold increase in Cmax mean?
It means the tested self-emulsifying preparation produced a peak plasma BCP concentration approximately 3.6 times that of the comparison oil in the study. It does not mean a 3.6-fold improvement in clinical effectiveness.
Are liposomal BCP and nanoemulsified BCP the same?
No. Liposomes are phospholipid-based vesicles, while self-emulsifying and nanoemulsion systems use different dispersion structures. Their actual absorption performance depends on the specific preparation.
Does BCPlus Liposomal Drops have the same absorption results as VESIsorb?
The cited human study did not test BCPlus Oral Liposomal Drops. Its findings cannot establish an equivalent absorption improvement for BCPlus without a direct product-specific study.
Is BCPlus Nano Powder proven to absorb better than BCP oil?
BCPlus Nano Powder is formulated with dispersion and delivery characteristics in mind, but the cited studies did not measure its finished-product absorption in humans. Its actual comparative human bioavailability remains to be established.
What the absorption research reveals
Beta-caryophyllene's delivery system can substantially affect how much of the compound reaches circulation.
The 2022 human study offers direct evidence that one self-emulsifying preparation produced greater exposure and faster absorption than ordinary BCP oil.
The 2026 animal investigation adds research into nanoemulsifying delivery systems and their biological behavior.
Together, these findings help explain why formulation deserves serious attention when studying a lipophilic botanical compound.
The next question is how individual finished products perform under controlled conditions.
For consumers and researchers, the most reliable approach is to compare the specific ingredients, delivery technologies, doses and measured outcomes of the actual preparation.
That is where formulation science becomes meaningful evidence.
Explore physician-formulated BCPlus products
Blair Medical Group develops physician-formulated BCPlus supplements using delivery approaches selected for the physical and chemical properties of beta-caryophyllene. Its oral product collection includes liposomal liquids and a specialized nano-terpene powder, offering different preparation formats for people exploring BCP supplementation.
Both products can be evaluated by their current ingredient lists, serving information and manufacturer documentation. The studies discussed in this article demonstrate why delivery design matters, while product-specific clinical absorption and effectiveness require their own measurements.
BCPlus Oral Liposomal Drops 60 mL
BCPlus Nano Powder
Primary research
Mödinger Y, et al. (2022). Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using VESIsorb Formulation Technology. Molecules. DOI: 10.3390/molecules27092860. HUMAN — randomized crossover pharmacokinetic study.
Chagas-Almeida AC, et al. (2026). Improving the Oral Bioavailability and Anti-Inflammatory Potential of Clove Oil-Derived β-Caryophyllene with a Self-Nanoemulsifying Drug Delivery System. Journal of Pharmacy and Pharmacology. DOI: 10.1093/jpp/rgaf105. ANIMAL–PRECLINICAL / FORMULATION.
Correction to Chagas-Almeida et al., May 2026. DOI: 10.1093/jpp/rgag053. PUBLICATION CORRECTION — first-author name and graphical abstract.
Research reviewed: November 9, 2026 Article type: Selected narrative review of BCP bioavailability and formulation research Publisher: Blair Medical Group Medical review: Pending





Comments